Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP 5

Novo Nordisk · Phase 3 · Completed · Enrollment 304

NCT03693430

EudraCT 2017-003726-32

ArmPopulationDoseWeeksEstimandWeight change
SemaglutideObesity or overweightn/r4Efficacyn/r
PlaceboObesity or overweightn/r4Efficacyn/r
Semaglutide 2.4 mg, in trialObesity or overweight2.4 mgn/rITTn/r
Placebo, in trialObesity or overweightn/rn/rITTn/r